noom glp-1 companion Med Noom GLP 1

Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients With Cushings Disease During Active Disease and 1 Year After Disease Remission

Combining prolonged fasting, severe calorie restriction, intense exercise, and GLP-1 therapy at the same time can raise the risk of fatigue, dizziness, dehydration, poor nutrition, and lean muscle loss

Drug patents last 20 years, but that time frame includes the many years it takes to test a drug before its brought to market

GLP-1s were associated with a significant reduction in body weight in 15 studies and improved glycemic control in eight studies enrolling people with mental illness

Henderson SJ, Konkar A, Hornigold DC et al (2016) Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates